Meeting
2018 Genitourinary Cancers Symposium
Proportion of biochemically-recurrent prostate cancer patients with durable undetectable PSA after short-course androgen deprivation therapy.
Authors
Daniel M. Lim
University of Washington, Seattle, WA
Daniel M. Lim , Roman Gulati , Serge Aleshin-Guendel , Heather H. Cheng , Agnes M. Gawne , Jonathan T. Wingate , Ruth Douglas Etzioni , Evan Y. Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 207)
DOI
10.1200/JCO.2018.36.6_suppl.207
Abstract #
207
Poster Bd #
K5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC): ZZFIRST.
First Author: Joaquin Mateo
Poster
2017 Genitourinary Cancers Symposium
Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Phillip Lee Palmbos
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
First Author: Grace G Kim